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Objective: We tested whether the CardioClasp device (CardioClasp, Inc, Cincinnati,
Ohio), a non-blood contact device, would improve left ventricular contractility by
acutely reshaping the left ventricle and reducing left ventricular wall stress.
Methods: In dogs (n  6) 4 weeks of ventricular pacing (210-240 ppm) induced
severe heart failure. Left ventricular function was evaluated before and after
placement of the CardioClasp device, which uses 2 indenting bars to reshape the left
ventricle. Hemodynamics, echocardiography, and Sonometrics crystals dimension
(Sonometrics Corporation, London, Ontario, Canada) were measured at steady state
and during inferior vena caval occlusion.
Results: The CardioClasp device decreased the left ventricular end-diastolic ante-
rior-posterior dimension by 22.8%  1.9%, decreased left ventricular wall stress
from 97.3  22.8 to 67.2  7.7 g/cm2 (P  .003), and increased the fractional area
of contraction from 21.3%  10.5% to 31.3%  18.1% (P  .002). The clasp did
not alter left ventricular end-diastolic pressure, left ventricular pressure, left ven-
tricular dP/dt, or cardiac output. With the CardioClasp device, the slope of the
end-systolic pressure-volume relationship was increased from 1.87 0.47 to 3.22
1.55 mm Hg/mL (P  .02), the slope of preload recruitable stroke work versus
end-diastolic volume was increased from 28.4  11.0 to 44.1  23.5 mm Hg (P 
.02), and the slope of maximum dP/dt versus end-diastolic volume was increased
from 10.6  4.6 to 18.6  7.4 mm Hgs1mL1 (P  .01). The CardioClasp
device increased the slope of the end-systolic pressure-volume relationship by
68.0%  21.7%, the slope of preload recruitable stroke work versus end-diastolic
volume by 50.7%  18.1%, and the slope of maximum dP/dt versus end-diastolic
volume by 85.7%  28.9%.
Conclusions: The CardioClasp device decreased left ventricular wall stress and
increased the fractional area of contraction by reshaping the left ventricle. The
CardioClasp device was able to maintain cardiac output and arterial pressure. The
clasp increased global left ventricular contractility by increasing the slope of the
end-systolic pressure-volume relationship, the slope of preload recruitable stroke
work versus end-diastolic volume, and the slope of maximum dP/dt versus end-
diastolic volume. In patients with heart failure, the CardioClasp device might be
effective for clinical application.
With heart failure, left ventricular (LV) enlargement places anincreased wall tension on the individual myocytes. Thisincreased wall tension, together with cardiomyocyte dys-function, leads to a profound depression in global LV func-tion and contractility. If this extra geometric burden causedby ventricular dilatation can be eliminated, myocardial wall
stress would decrease, leading to improved LV systolic ventricular performance.
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Melvin1 was the first to examine the concept of passive
ventricular remodeling to reduce this geometric burden.
Using a computational analysis, he showed that by impos-
ing a shape change on a dilated left ventricle, the ratio of
wall tension to chamber pressure was reduced. On the basis
of this concept, the CardioClasp device (CardioClasp, Inc,
Cincinnati, Ohio) was developed. The CardioClasp device
is a passive cardiac support device (CSD) that uses 2 in-
denting bars to reshape the left ventricle as 2 widely com-
municating lobes of reduced radius.
By passively reshaping the left ventricle and decreasing
the radius of curvature, the CardioClasp device reduces LV
wall stress.1 In previous studies passive reshaping has been
shown to increases LV ejection fraction without altering
cardiac output or systolic pressures.2-9 In the present study,
using a dilated heart failure model, we tested whether the
CardioClasp, by passively reshaping the left ventricle and
reducing LV wall stress, can improve global LV contractil-
ity.
Methods
All study procedures were performed in compliance with the
“Principles of Laboratory Animal Care” formulated by the Na-
tional Society for Medical Research and the “Guide for Care and
Use of Laboratory Animals” issued by the National Academy of
Sciences and published by the National Institutes of Health (Na-
tional Institutes of Health publication, revised 1996).
Induction of Heart Failure
After an overnight fast, 6 mongrel dogs (22.5-26.7 kg) were
anesthetized with intravenous sodium thiopental (15-25 mg/kg)
and intramuscular atropine (0.01 mg/kg), intubated, and mechan-
ically ventilated (model R-DRAGERAV, S/N. R-2035, North
American Dra¨ger, Telford, Pa). Anesthesia was maintained with
1% to 2% isoflurane (Isoflurane Vaporizer, Oharda; Isotec 3,
Aushell, Ga) and oxygen. Surface electrocardiographic results
(model 78346A; Hewlett Packard, Palo Alto, Calif) and oxygen
saturation were monitored continuously.
As described previously, a bipolar, implantable, screw-in,
transvenous myocardial pacing lead (model 4058; Medtronic, Min-
neapolis, Minn) was introduced through the right jugular vein and
positioned at the right ventricular apex during fluoroscopy.2,10 The
pacing lead was tunneled to the back of the neck and connected to
a pulse generator (THERAs model 8966i B, Medtronic) implanted
subcutaneously through a 4- to 5-cm incision. The pacemaker
generator was secured with the underlying muscle, and all the
wounds were closed in layers.
Rapid right ventricular pacing was started on the second post-
operative day. During the first week, pacing parameters were 210
ppm, 3.5-V pulse amplitude, 2.8-mV pulse sensitivity, and 1.5-ms
pulse width. The pacing rate was increased consecutively to 220,
230, and 240 ppm during the second, third, and fourth weeks,
respectively.2,10 As in previous studies, incremental pacing reli-
ably induced congestive heart failure manifested by clinical find-
ings of ascites, muscle wasting, lethargy, and decreased appetite.
Evaluation of the CardioClasp Device
The heart failure animals were anesthetized with a combination of
intravenous injections of diazepam (1 mg/kg), fentanyl citrate (2-8
g/kg), and 2% lidocaine (1 mg/kg). The animals were ventilated
through an endotracheal tube with a positive-pressure respirator
(North American Dra¨gger, model R-DRAGERAV, S/N. R-2035)
and maintained with 1% to 2% isoflurane. The electrocardiogram
was monitored continuously. An oxygen saturation monitor
(52000 series, S/N. 9801168, WelchAllyn; Tycos Instruments Inc,
Ithaca, NY) to measure the oxygen saturation was used continu-
ously.
After administering 3000 units of heparin, a 6F micromanom-
eter-tipped pigtail catheter (Millar Inc, Houston, Tex) was inserted
and advanced to the left ventricle for measurement of the LV
pressure. The side port of the catheter sheath was connected to a
fluid transducer for measuring the arterial pressure. With the
animal in the right lateral position, a left lateral thoracotomy was
performed at the fifth intercostal space. The pericardium was
opened by using a fine scissor, and the heart was suspended in a
pericardial cradle. A flow probe (A-series 16-mm, S/L no.16A320;
Transonic Systems Inc, Ithaca, NY) was placed around the ascend-
ing aorta and connected to a flowmeter (model T206, S/L no.
1206-S-991539, Transonic Systems Inc) to measure aortic flow.
A balloon occlusion catheter (8F, 40-mm balloon; Boston Sci-
entific Corp, Natick, Mass) introduced through the right femoral
vein was placed at the junction of the inferior vena cava (IVC) and
right atrium. When required in the protocol, inflating this balloon
obstructed flow in the IVC, thereby gradually decreasing cardiac
output.
Sonometric crystals placement. Six small piezo electric Sono-
metrics crystals (Sonomicrometer Crystals; Sonometrics Inc, On-
tario, Canada) were placed into the endocardial positions in the
anterior, posterior, apex, base, free, and septal walls to assess LV
volume (end-systolic pressure-volume relationship [ESPVR]).
Crystal dimensions were measured continuously (Sonometrics
Data Acquisition System, Sonometrics Inc).
Description of the CardioClasp device. The CardioClasp is an
implantable medical device that consists of 3 primary components:
2 rigid bars with pads and an adjustable tether. The rigid bars have
a defined curvature similar to that of the heart. Longitudinally and
torsionally flexible contact pads are attached to each bar. An
adjustable tether connects the 2 pad-bar assemblies on either side
of the left heart.
Placement of the CardioClasp device. All pulmonary veins
were mobilized from the superior to inferior aspects, and a guiding
catheter was introduced underneath the pulmonary veins. The
posterior bar of the CardioClasp was positioned along the long axis
of the left ventricle adjacent to the posterior descending artery, and
the anterior bar of the device was placed along the long axis of the
left ventricle adjacent to the left anterior descending coronary
artery. The anterior and posterior bars were connected with a tether
to an adjustment tool. The device, once implanted, was secured to
the left heart by means of mechanical fixation. Once the device
was fixed, the adjustment tool pulled the tether, shortening the
distance between the anterior and posterior bars and thereby de-
creasing the LV anterior posterior (A-P) dimension. We measured
a baseline A-P end-diastolic dimension at the papillary muscle
level in a short-axis echocardiographic view. After tightening the
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CardioClasp with the adjustment tool, the percentage of A-P
dimension reduction was confirmed by using the short-axis echo-
cardiographic view at the papillary muscle level.
Measurements
At baseline, the echocardiographic results, arterial and LV pres-
sure, and aortic flow were measured, recorded, and digitized on a
recorder (VIPER, Gould, Ohio). With the respirator off, these
measurements were obtained under steady-state conditions and
during IVC occlusions. In each experiment 3 IVC runs at baseline
were recorded.
Echocardiographic measurements were obtained by using an
HP Sonos 5500 machine (Hewlett Packard). All studies were
performed on animals with an open chest and using an epicardial
window. An s12 multifrequency transducer (Hewlett Packard) set
at the midrange frequency was placed over the LV free wall by
using a stand-off gel pad to obtain images. Fine epicardial sutures
for repositioning marked the probe position. Two-dimensional
short-axis images of the left ventricle were obtained at the level of
the papillary muscle. LV internal dimensions were measured from
these 2-dimensional images. End-diastolic measurements were
obtained at the peak of the R wave on the electrocardiogram.
End-systolic measurements were obtained at the end of the T
wave.
After obtaining the baseline measurements, the CardioClasp
was placed on the heart, and the LV A-P internal end-diastolic
dimension was reduced by approximately 25%. Echocardiograms
were obtained. Hemodynamic data were acquired with the Cardio-
Clasp. The echocardiographic results, arterial and LV pressure,
and aortic flow were recorded with the respirator off. These mea-
surements were obtained under steady-state conditions and during
IVC occlusions similar to the baseline measurements.
Finally, the animal was killed with 2 mEq/kg potassium chlo-
ride (20-30 mL of KCl) administered intravenously and 15 mg/kg
sodium pentothal (10-15 mL) administered intravenously.
Data Analysis
Echocardiography. The echocardiographic images at end sys-
tole and end diastole were captured by the Hewlett-Packard Echo-
cardiography machine (Sonos 5500), where the LV end-diastolic
and end-systolic areas’ (short-axis view) endocardial borders were
traced. The dimensional and area information were used to calcu-
late the area ejection fraction or fractional area of contraction
(FAC) as follows:
FAC  (LVEDA–LVESA)/LVEDA  100
where LVDEA is defined as LV end-diastolic area, and LVESA is
defined as LV end-systolic area.
Peak LV wall stress was calculated as follows:
LVWS  (0.334  LVP  LVD)/[WT (1 WT/LVD)]
where LVP is defined as LV systolic pressure, LVD is defined as
LV anterior posterior diameter, and WT is defined as LV wall
thickness.11,12
Hemodynamics. By using software developed in Visual Basic
for Excel (Microsoft Excel 7.0; Microsoft Inc, Redwood, Wash),
hemodynamic variables were extracted from a digitally stored data
file. Ectopic and postectopic cycles were excluded from the anal-
ysis. For each cardiac cycle, the end-diastolic pressure, the peak
ventricular systolic pressure, LV dP/dt, LV dP/dt, and peak
and end-diastolic aortic pressures were determined, and stroke
volume and work were calculated.
Indices of contractility. Multiple LV pressure-volume loops
were obtained during transient preload reduction induced by oc-
cluding the IVC. Premature beats and subsequent beat were ex-
cluded from the analysis. LV contractility was assessed by the
end-systolic pressure-volume (PES-VES) relationship (PES 
EES[VESVO], where EES is the slope of the ESPVR)13, the
preload recruitable stroke work (SW) versus end-diastolic volume
(SW  MSW [VEDVO,SW]) relationship (MSW),14 and the max-
imum dP/dt versus VED (dP/dtMAX  dE/dtMAX[VEDVO,SW])
relationship.15
Data are expressed as means  SD. The hemodynamic, echo-
cardiographic, and indices data at baseline were compared with
those during use of the CardioClasp by using the paired Student t
test.
Results
Figure 1 shows 2 representative LV short-axis echocardio-
graphic views at the papillary muscle level at baseline and
with the CardioClasp. The LV short-axis views were ob-
tained at end diastole. With the CardioClasp, the LV A-P
diameter was reduced by 25%, from 4.56 to 3.43 cm.
Fractional areas of contractions were increased by 22.0%. In
the group data echocardiographic images revealed that the
CardioClasp device reduced the end-diastolic LV A-P di-
mension by 22.8%  1.9%. Associated with this shape
change, the CardioClasp decreased LV end-diastolic area by
20.4% 5.0% and LV end-systolic area by 25.1% 9.5%.
Table 1 presents the absolute values for echocardio-
graphic parameters at baseline and with the CardioClasp.
With the CardioClasp, end-systolic and end-diastolic LV
A-P and septal free wall thickness were increased slightly.
End-diastolic septal free wall dimension were unchanged,
whereas end-systolic septal free wall dimensions were in-
creased (P  .022).
With the CardioClasp (Figure 2), myocardial LV wall
stress decreased significantly from baseline values (97.3 
22.8 to 67.2  7.7 g/cm2, P  .003). The CardioClasp
decreased myocardial LV wall stress by 28.9%  4.4%
compared with baseline values.
With the CardioClasp (Figure 3), the FAC increased
significantly from baseline (21.3  10.5 to 31.3  18.1,
P  .002). The CardioClasp increased FAC significantly by
50.9%  18.1% compared with baseline values.
From one experiment, Figure 4 shows different indices
of LV contractility. In Figure 4, A, LV pressure-volume
loops are plotted at baseline and with the CardioClasp
together with the ESPVRs. In this example the CardioClasp
increased the slope of the ESPVR. Figure 4, A, shows one
example of ESPVR loops generated during the baseline
period and with the CardioClasp at 25%. The data show a
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steepening of the LV ESPVR slope (increased Emax) at
25%.
Figure 4, B, shows the effects of the CardioClasp on
preload recruitable stroke work. The rounded bullets and
solid line represent the SW-EDV relationship with the Car-
dioClasp and the dotted line with solid bullets represents the
SW-EDV relationship at baseline. Clearly, the CardioClasp
increased the SW-EDV relationship compared with baseline
values.
Figure 4, C, shows the effects of the CardioClasp on
dE/dt, the slope of the maximum dP/dt–VED(dP/
dtMAXVED) relationship. The rounded bullets and solid
line represent dE/dt with the CardioClasp, and the dotted
line with solid bullets represents dE/dt at baseline. The
CardioClasp increased dE/dt compared with baseline val-
ues.
Table 2 presents the absolute hemodynamic parameters
at baseline and with the CardioClasp. With the CardioClasp,
cardiac output was unaltered (P  .40). Likewise, peak LV
systolic (P .26) and LV end-diastolic (P .43) pressures,
peak positive (P  .12) and negative (P  .23) first deriv-
atives of LV pressures (dP/dts), and aortic systolic (P .38)
and diastolic (P  .12) pressures were unaltered.
LV contractility, assessed by means of EES, MSW, and
dE/dtMAX, was significantly greater in the CardioClasp-
treated group than in the baseline heart failure group. Table
Figure 1. Two representative LV end-diastolic short-axis echocardiographic views at papillary muscle level at
baseline heart failure and with the CardioClasp. The CardioClasp significantly reduced LV A-P diameter by 25%.
The figure shows how the A-P dimension was measured connecting the line immediately below to the anterior and
posterior papillary muscles of the left ventricle (A, corner point of the anterior papillary muscle; P, corner point
of the posterior papillary muscle). In this image the anterior bar of the CardioClasp device was in front of the
anterior papillary muscle and not visible. The posterior bar of the CardioClasp device was at the back of the
posterior papillary muscle and poorly visible (slightly echogenic behind the papillary muscle).
TABLE 1. Effects of the CardioClasp on echocardiographic parameters
LV echocardiographic parameters Baseline CardioClasp P value
Diastole A-P dimension (cm) 4.31 0.34 3.39 0.34* .0001
S-FW dimension (cm) 4.04 0.34 4.04 0.42 .488
A-P wall thickness (mm) 9.6 2.1 9.7 1.3 .431
S-FW wall thickness (mm) 9.4 1.7 9.5 1.1 .485
End-diastolic area (cm2) 12.2 2.1 9.7 2.3* .007
Systole A-P diameter (cm) 3.73 0.36 3.10 0.44* .0001
S-FW dimension (cm) 3.70 0.55 3.92 0.54* .022
A-P wall thickness (mm) 10.0 1.7 11.1 2.2* .040
S-FW wall thickness (mm) 10.1 1.6 11.3 2.2 .052
End-systolic area (cm2) 10.8 2.6 8.0 3.1* .034
S-FW, Septal free wall.
*P  .05.
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3 shows the systolic indices of the pressure-volume rela-
tionship at baseline and with the CardioClasp. With the
CardioClasp, Emax increased by 68.0%  21.7% (P  .02),
preload recruitable stroke work increased by 50.7% 
18.1% (P  .02), and dE/dt increased by 85.7%  28.9%
(P  .01).
Discussion
The concept and understanding of passive LV geometric
reshaping is evolving. Melvin1 was the first to examine the
concept of passive geometric ventricular remodeling by
using a computational analysis. The model showed that by
imposing a shape change on a dilated left ventricle, the ratio
of wall tension to chamber pressure was reduced. If the
reduction in wall tension occurred as a result of ventricular
resection, then a substantial degree of contractile shortening
improvement would be needed just to maintain baseline
stroke volume.
Shimizu and colleagues3 examined the effects of passive
LV reshaping in a canine model of dilated heart failure.
After rapid ventricular pacing induced heart failure, the
heart was attached to an isolated heart preparation. The
CardioClasp was positioned on the heart and adjusted to
reduce A-P end-diastolic dimension by 20% to 30%. With
the CardioClasp, the ESPVR was significantly increased
from 1.4 mm Hg/mL at baseline to 2.4 mm Hg/mL. After
taking off the device, ESPVR returned to the baseline level
(1.5 mm Hg/mL). Shimizu and colleagues also showed that
both the systolic and diastolic pressures and the developed
pressure decreased with rapid removal of the CardioClasp.
Earlier, our group reported acute hemodynamic improve-
ments with the CardioClasp at approximately 30% and 15%
LV end-diastolic dimension reduction.2 We showed LV
dimension reduction at 31.3%, and the FAC was increased
by 27%.
Santamore and coworkers4 reported that at normal after-
load, the CardioClasp maintained the stroke volume versus
end-diastolic pressure relationship. At increased afterload,
the decrease in the stroke volume versus end-diastolic pres-
sure relationship was less with the CardioClasp. Santamore
and coworkers also reported that LV reshaping with the
CardioClasp attenuated the cardiac output decrease in re-
sponse to increased afterload. With increased afterload, the
stroke volume decreased significantly less with the Cardio-
Clasp (20.4%  0.4%) compared with control values
(27.7%  0.6%, P  .05).
In our experiments the CardioClasp acutely reduced the
LV A-P diameter by 22.8%, as demonstrated by means of
direct epicardial transthoracic echocardiography. The Car-
dioClasp device also significantly reduced the LV systolic
wall stress by 29%. Our measurement of FAC clearly
showed the effective results with the passive CardioClasp
device; the FAC was increased by 51% with the Cardio-
Clasp at implantation. In these experiments the CardioClasp
increased Emax by 68.0%, Msw by 50.7%, and dE/dtMAX by
85.7%, indicating improved LV myocardial contractility.
Baseline LV systolic and diastolic pressures were not
significantly altered compared with pressures with use of
the CardioClasp. Likewise, cardiac output was unaltered
with use of the CardioClasp at implantation (1.9 L/min)
compared with baseline heart failure. The reason for in-
creased ejection fraction and contractility with unaltered
cardiac output (1.9 L/min) probably lies in the decreased LV
end-diastolic volume, as evidenced by the decreased end-
diastolic areas after CardioClasp placement.
The key findings of the present study are the following:
1. The CardioClasp reshaped the left ventricle, thereby
reducing the LV systolic wall stress.
2. The FAC increased, whereas cardiac output and LV
pressure were unaltered.
3. The CardioClasp significantly increased global LV
contractility, as indicated by the increases in Emax,
MSW, and the slope of the maximum dP/dt–VED(dE/
dtMAX) relationship.
Figure 3. Significantly increased LV FAC by 50.9%  18.1% with
the CardioClasp. *P < .05.
Figure 2. Significantly decreased LV wall stress (LVWS) with the
CardioClasp by 28.9%  4.4%. *P < .05.
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Comparison with the Literature
The Myosplint device pulls the opposing walls of the heart
together, thereby decreasing the chamber radius. Each Myo-
splint implant consists of 2 epicardial buttons connected by
a tension member that bisects the left ventricle. The Myo-
splint buttons (generally 3 sets) are placed down the long
LV axis to create a bilobular shape.5-7 In initial experimental
studies Takagaki and associates6 confirmed acute LV shape
changes induced by the Myosplint and showed that this
passive device was associated with a 20% decrease in wall
stress and an increase in LV ejection fraction. Cardiac
output and ventricular pressures were unaltered. These ben-
efits were maintained over 30 days.5 Peak LV elastance and
preload recruitable stroke work increased from baseline to 4
weeks after placing the Myosplint.7
In human subjects the Myosplint was initially tested in
patients awaiting heart transplantation. Placed just before
removing the heart, this passive device decreased peak LV
systolic wall stress.8 In an initial clinical series the device
was implanted in 5 patients in New York Heart Association
class III with dilated cardiomyopathy.8,9 Placement of the
Myosplints was safely performed without early significant
Figure 4. A, Representative recordings showing LV pressure-volume loops at baseline heart failure and during
CardioClasp placement at 25% LV dimension reduction. LV contractility assessed by Emax was significantly higher
by 68.0%  21.7% with the CardioClasp (P  .01 compared with baseline heart failure). LVV, LV volume; LVP, LV
pressure. B, Preload recruitable stroke work (SW) versus end-diastolic volume (EDV) relationship at baseline heart
failure (solid bullets and dotted line) and with the CardioClasp (rounded bullets and solid line). The CardioClasp
significantly increased the preload recruitable stroke work– end-diastolic volume relationship (P  .02). MSW,
Slope of the LV preload recruitable stroke work (in millimeters of mercury); EDV, LV end-diastolic volume (in
millimeters). C, Slope of the maximum dP/dt–VED (dP/dtMAX–VED) relationship (dE/dt) at baseline heart failure (solid
bullets and dotted line) and with the CardioClasp (rounded bullets and solid line). The CardioClasp significantly
increased dE/dt (in millimeters of mercury per second per milliliter), (P  .02). LVdP/dt, First derivative of the LV
pressure (in millimeters or mercury per second); EDV, LV end-diastolic volume (in milliliters).
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adverse events. However, reconfiguration of the left ventri-
cle by the Myosplints might necessitate simultaneous mitral
valve repair in patients with clinically significant incompe-
tence.16
Passive Cardiac Restraint
The results of cardiomyoplasty have led to the development
of passive devices to constrain the heart and prevent further
ventricular dilatation.17,18 One such device is the Acorn
CorCap CSD. The Acorn CorCap CSD is a mesh-like jacket
that is slipped around the heart and adjusted to prevent the
heart from further dilatation.
Most experimental studies with the Acorn device have
involved induction of heart failure, placement of the device,
and then, weeks to months later, examination of ventricular
function. In an experimental study Chaudhry and cowork-
ers19 produced heart failure by means of intracoronary mi-
croembolization. In the control animals LV size continued
to increase, and ejection fraction decreased. In the Acorn-
supported animals, LV size decreased slightly, and ejection
fraction increased. Sabbah and associates20 showed that the
percentage of myocyte shortening and the peak velocity of
shortening (dS/dt) were significantly increased in CSD-
treated dogs undergoing heart failure. In a rapid ventricular
pacing heart failure model, Power and colleagues21 reported
higher LV fractional shortening and less mitral regurgitation
in Acorn-support animals. In sheep 1 week after coronary
artery ligation, Pilla and associates22,23 placed the Acorn
CSD around the heart. At terminal study, infarct size was
significantly smaller, and ventricular function was signifi-
cantly better in the Acorn-supported animals.
In patients with idiopathic cardiomyopathy, Konertz and
coworkers24 reported a decrease in LV end-diastolic and LV
end-systolic diameters and an increase in LV ejection frac-
tion by using the Acorn device in patients. These benefits
were maintained at 1 year.24,25 Six patients with symptom-
atic heart failure caused by ischemic cardiomyopathy were
treated surgically with the Acorn CSD and underwent cor-
onary artery bypass grafting.24-26 Ventricular reconstruction
was also performed in 5 of the 6 patients. Both the LV
end-diastolic and LV end-systolic diameters were signifi-
cantly decreased 1 month postoperatively and did not
change significantly over the next 11 months. Mitral regur-
gitation improved from a mean of 2.7 preoperatively to 1.4
at 12 months, and the average LV ejection fraction also
increased from 27% preoperatively to 35.9% at 12 months
after surgical intervention.25
Limitations of the Study
Despite the fact that we used a dilated cardiomyopathy
animal model, the mechanism and dilatation in pacing-
induced cardiomyopathy is different than that in the human
idiopathic cardiomyopathy and poorly understood. Further
chronic studies are to be carried out to understand the
chronic changes and effects of CardioClasp device place-
ment on dilated cardiomyopathy. Currently, at Temple Uni-
versity, we have started chronic studies with a pacing
model, in which the CardioClasp is implanted for 30 days.
After device implantation, the pacing parameters are con-
tinued to maintain the heart failure model. We reported a
preliminary report27 of chronic data as an abstract (n 4) at
the 2002 American Society for Artificial Internal Organs
meeting. After 30 days of chronic implantation, the epicar-
dial area underneath the anterior and posterior bars showed
fibrous tissue formation underneath the pads. However,
histologic epicardial and myocardial samples did not show
any ischemic changes related to the pads. No necrosis or
myocardial injury was present at the compression sites by
the bars of the CardioClasp device. As the numbers of
animals were few, further randomized chronic studies with
sham operations are to be carried out for statistical differ-
ences. These results can be used to focus on the effects of
the CardioClasp in dilated cardiomyopathy and might be
closer to those of surgical intervention for clinical dilated
cardiomyopathy.
Summary and Conclusions
The goal of medical management of heart failure is to
reduce afterload. This is usually achieved by lowering vas-
cular resistance. The resulting lower arterial blood pressure
TABLE 3. Effects of the CardioClasp on LV contractility
Emax
(mm Hg/mL)
MSW
(mm Hg)
dE/dtmax
(mm Hg  s1  mL)
Baseline 1.87 0.47 28.4 11.0 10.60 4.58
Clasp 3.22 1.55* 44.1 23.5* 18.58 7.42†
Emax, Slope of LV ESPVR; MSW, slope of preload recruitable stroke work
versus end-diastolic volume; dE/dtmax, slope of the maximum dP/dt–VED
(dP/dtmax–VED) relationship.
*P  0.02 and †P  0.01 when compared with baseline values.
TABLE 2. Effects of the CardioClasp on hemodynamic pa-
rameters
Hemodynamic parameters Baseline heart failure CardioClasp
LVEDP (mm Hg) 17.5 3.1 17.9 4.3
LVSP (mm Hg) 80.3 12.4 82.4 16.9
Max dP/dt (mm Hg/s) 782 223 956 519
Min dP/dt (mm Hg/s) 700 151 786 291
AoPsys (mm Hg) 78.4 12.0 79.5 16.6
AoPdias (mm Hg) 52.0 4.6 58.4 13.4
CO (L/min) 1.9 0.4 1.9 0.5
LVEDP, Left ventricular end-diastolic pressure; LVSP, left ventricular peak
systolic pressure; Max dP/dt, peak first positive derivative of the left
ventricular pressure; Min dP/dt, peak first negative derivative of the left
ventricular pressure; AoPsys, peak systolic aortic pressure; AoPdias, peak
diastolic aortic pressure; CO, cardiac output.
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can compromise blood flow to other vital organs, such as the
brain and kidney. The CardioClasp device can reduce the
tension on the myocardial cells without decreasing arterial
blood pressure. This leads to improved LV systolic perfor-
mance. The CardioClasp significantly increased the stroke
work versus end-diastolic volume relationship and the slope
of the maximum dP/dt–VED(dE/dtMAX) relationship, and
Emax was also significantly increased by the CardioClasp.
With overall increased LV systolic indices and contractility,
this passive geometric ventricular reshaping has the added
potential for preserving the contractile mass and circumfer-
ential length.
We thank Dr Milton April and Lewis Bright for their dedicated
support and animal care for this experiment.
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Discussion
Dr W. Randolph Chitwood (Greenville, NC). Dr Kashem, I
think you have done an eloquent job in studying physiologically
the changes associated with these new devices, which we hope will
provide great improvement in hemodynamics for patients with
these terribly dilated ventricles. They really had no hope in the
past. We congratulate you on your work. I have several question-
s.The first question is, how is this device incorporated into heart
tissue? Did you do any studies looking at the incorporation of the
device into the myocardium?
Dr Kashem. We checked with the histology from chronic and
acute studies, and we did not find any problem with the histology,
and there was no significant abrasion incorporating the device over
to the myocardium. Histologically, it did not show any gross
abnormalities of the myocardium.
Dr Chitwood. After this device is working and active, does it
change papillary muscle function, tip distance, or angulation with
the leaflets through the chords? Was there any mitral insufficiency
seen in these patients?
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Dr Kashem. No, we did not present those date here, but at the
International Society for Heart and Lung Transplantation meeting,
I presented the mitral regurgitation. We performed transesophageal
echocardiography in all the animal studies, which we did not show
here, and I found there are no changes in mitral regurgitation.
Mostly in heart failure we found that mitral regurgitation was
grade 1 to 2 in most cases, and we found there was no significant
alteration of the mitral regurgitation in those cases.Regarding
papillary muscle, I did not see any implications with the Cardio-
Clasp device.
Dr Chitwood. Do you think this device could actually be used
in a different way to reorient papillary muscles in patients who
have ischemic mitral regurgitation or cardiomyopathic mitral re-
gurgitation? Can you reorient the chordae? Could this device
decrease mitral insufficiency?
Dr Kashem. We did not investigate the means of the place-
ment. We did investigate several ways to place the device, and we
did not find any significant changes. But maybe in the future we
can see whether there are any significant effects on the papillary
muscle or mitral regurgitation by placing the device.
Dr Chitwood. How does this device differ from the Myocor
and Acorn devices in its efficacy?
Dr Kashem. The basic theory for the Myocor and CardioClasp
is the same—to reduce wall stress—but the important thing here is
that it is a non-blood contact device for CardioClasp. It does not
penetrate the left ventricle. The other one has a bilobular shape,
and the CardioClasp does the same thing. Compared with the
Acorn device, the CardioClasp device has an immediate effect on
contractility and an immediate effect on reduction of the wall
stress and tension on the myocardial cells. It should have a reverse
remodeling in long-term cases; we did not study those cases. I
guess a 3-month or 6-month study could answer the question of
whether there is a reverse remodeling at the myocyte level.
Dr Chitwood. It would be interesting to compare these devices
as to their efficacy and efficiency using your hemodynamic mod-
els.
Dr Kashem. Yes.
Dr Chitwood. What is the ideal target patient population for
these devices?
Dr Kashem. Mostly patients undergoing dilated cardiomyop-
athy of ischemic or nonischemic origin. The CardioClasp device
could be placed in New York Heart Association class III or IV
patients. But we still have to go further on the inclusion-exclusion
criteria. We did not decide that.
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